Section Arrow
AMGN.NASDAQ
- Amgen
Quotes are at least 15-min delayed:2024/10/31 21:06 EDT
Last
 320.27
+4.73 (+1.50%)
Day High 
323.4 
Prev. Close
315.54 
1-M High
329.17 
Volume 
2.71M 
Bid
315
Ask
319.99
Day Low
315.65 
Open
317.69 
1-M Low
310.63 
Market Cap 
169.55B 
Currency USD 
P/E 55.17 
%Yield 2.77 
10-SMA 317.57 
20-SMA 319.55 
50-SMA 324.65 
52-W High 346.85 
52-W Low 255.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
5.80/20.34
Enterprise Value
232.72B
Balance Sheet
Book Value Per Share
11.03
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
381.20M
Operating Revenue Per Share
46.83
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PFEPfizer28.3-0.22-0.77%76.86PE
BMYBristol-Myers Squibb Co55.77+3.11+5.91%11.67PE
MRKMerck & Co102.32-2.51-2.39%19.39PE
GSKGSK plc36.76-0.25-0.68%12.75PE
ABBVABBVIE203.87+2.37+1.18%67.54PE
Quotes are at least 15-min delayed:2024/10/31 21:06 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launchesinclude Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growingbiosimilar portfolio.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.